China Biologic Products : CBPO 4Q20 Presentation Material

March 2021

(NASDAQ: CBPO)

CBPO 2020 Fiscal Year Financial Highlights

01

•  Revenue: $524.4 mm, up 4.3% in RMB terms(1) or 4.1% in USD terms y-o-y

•  Gross Profit: $344.4 mm, up 4.6% y-o-y; Gross Margin: 65.7%

•  Income from Operations: $195.4 mm, up 19.4% y-o-y; Operating Margin: 37.3%

•  Non-GAAP Adjusted Income from Operations(2): $244.1 mm, up 23.7% in RMB terms(1) or 23.1% in USD terms y-o-y

•  Net Income: $152.3 mm, up 9.7% y-o-y

•  Non-GAAP Adjusted Net Income(2): $196.1 mm, up 17.1% in RMB terms(1) or 16.4% in USD terms y-o-y

•  Fully diluted EPS: $3.82; Non-GAAP EPS(2): $4.92

• 1. We believe providing local currency information on certain key items of our financial results enhances the understanding of our financial results and evaluation of performance in comparison to prior periods. We calculate changes in local currency percentages by comparing financial results denominated in RMB from period to period.

• 2. Refer to Appendix for reconciliation of Non-GAAP income from operations, Non-GAAP net income attributable to equity holders and Non-GAAP EPS.

CBPO 4Q20 Financial Highlights

02

•  Revenue: $112.1 mm, up 3.2% in RMB terms(1) or 9.7% in USD terms y-o-y

•  Gross Profit: $74.6 mm, up 16.6% y-o-y; Gross Margin: 66.5%

•  Income from Operations: $32.6 mm, up 75.3% y-o-y; Operating Margin: 29.1%

•  Non-GAAP Adjusted Income from Operations(2): $46.4 mm, up 56.7% in RMB terms(1) or 66.9% in USD terms y-o-y

•  Net Income: $23.7 mm, up 89.6% y-o-y

•  Non-GAAP Adjusted Net Income(2): $36.2 mm, up 64.1% in RMB terms(1) or 74.9% in USD terms y-o-y

•  Fully diluted EPS: $0.59; Non-GAAP EPS(2): $0.91

• 1. We believe providing local currency information on certain key items of our financial results enhances the understanding of our financial results and evaluation of performance in comparison to prior periods. We calculate changes in local currency percentages by comparing financial results denominated in RMB from period to period.

• 2. Refer to Appendix for reconciliation of Non-GAAP income from operations, Non-GAAP net income attributable to equity holders and Non-GAAP EPS.

CBPO 4Q20 Business Highlights

03

• • 2020 annual plasma collection volume was comparable to 2019 as the Company explored various measures to make up for the reduced collection volume due to the pandemic in the first quarter.

• • In January 2021, Guizhou Taibang received the relevant operating permit and commenced operations at its new Youyang plasma collection station in Chongqing

  City.

This is an excerpt of the original content. To continue reading it, access the original document here.